Phase II pilot clinical trial of pazopanib in patients with relapsed or refractory acute myeloid leukemia (AML) or at initial diagnosis when no intensive treatment is possible

Beteiligte Wissenschaftler:
Akad. Rat Dr. Dipl.-Stat. J. Gerß
Dipl.-Stat. M. Eveslage

Studienleitung:
PD Dr. med. St. Koschmieder
PD Dr. med. T. Kessler